Companies: 10,795·Total market cap: $144.5T
Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGTNASDAQHealthcare● Active
$31.51
+$0.49(+1.58%)
Market Cap$5.4B
P/E Ratio
52W High$43.73
52W Low$5.485
Overview

Cogent Biosciences, Inc. (COGT) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001622229 · COGT · NASDAQ · as of Jun 8, 2026

Filing snapshot

595
Total Filings
4
Latest Form
2026-05-21
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001622229 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-17
Fiscal Year End
Feb 17, 2026
Accession No.
0001193125-26-053334
Primary Document
cogt-20251231.htm
Source: data.sec.gov · CIK 0001622229 · Accession 0001193125-26-053334

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-05
8-KCurrent Report
8-K
2026-05-05Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-14
View
10-QQuarterly Report
10-Q
2026-05-05
View
8-KCurrent Report
8-K
2026-05-05
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-31
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
S-8Employee Stock Plan Registration
S-8
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
10-KAnnual Report
10-K
2026-02-17
View
8-KCurrent Report
8-K
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-01-30
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-01-22
View
Showing 1–15 of 380 filingsForm 4 / 144 hidden· 595 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001622229  |  Exchange: NASDAQ · Healthcare

Cogent Biosciences, Inc. (NASDAQ: COGT) has submitted 595 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001622229, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Cogent Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Cogent Biosciences, Inc. 10-K was filed on 2026-02-17 for fiscal year ending 2026. Historical COGT 10-K annual reports are available from 2014 through 2026.

Investors researching Cogent Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

COGT SEC Filings · 8 questions

Cogent Biosciences, Inc. (COGT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 595 filings and access original documents at no cost. Cogent Biosciences, Inc.'s CIK is 0001622229.

COGT SEC filingsCogent Biosciences, Inc. SEC documentsfind COGT 10-K